Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.
Article
PubMed
Google Scholar
Solberg IC, Hoivik ML, Cvancarova M, et al. Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). Scand J Gastroenterol. 2015;50:1456–62.
Article
PubMed
Google Scholar
Williet N, Sandborn WJ, Peyrin Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1246–1256.e6.
Article
PubMed
Google Scholar
da Silva BC, Lyra AC, Rocha R, et al. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20:9458–67.
Article
PubMed
PubMed Central
Google Scholar
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A.
Article
PubMed
Google Scholar
Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dassopoulos T, Cohen RD, Scherl EJ, et al. Ulcerative colitis care pathway. Gastroenterology. 2015;149:238–45.
Article
PubMed
Google Scholar
Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and Management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–70.
Article
PubMed
Google Scholar
Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39:1095–103.
Article
CAS
PubMed
Google Scholar
D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol. 2010;7:86–92.
Article
PubMed
Google Scholar
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.
Article
PubMed
Google Scholar
Choung RS, Princen F, Stockfisch TP, et al. Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016;43:1300–10.
Article
CAS
PubMed
Google Scholar
Hamilton AL, Kamm MA, De Cruz P, et al. Serologic antibodies in relation to outcome in postoperative Crohn's disease. J Gastroenterol Hepatol. 2017;32:1195–203.
Article
CAS
PubMed
Google Scholar
Spekhorst LM, Imhann F, Festen EAM, et al. Cohort profile: design and first results of the Dutch IBD biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. BMJ Open. 2017;7:e016695.
Article
PubMed
PubMed Central
Google Scholar
Stevens TW, Matheeuwsen M, Lonnkvist MH, et al. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther. 2018;48:1213–31.
Article
PubMed
Google Scholar
Porter CK, Riddle MS, Gutierrez RL, et al. Cohort profile of the PRoteomic evaluation and discovery in an IBD cohort of tri-service subjects (PREDICTS) study: rationale, organization, design, and baseline characteristics. Contemp Clin Trials Commun. 2019;14:100345.
Article
PubMed
PubMed Central
Google Scholar
Dulai PS, Peyrin-Biroulet L, Danese S, et al. Approaches to integrating biomarkers into clinical trials and care pathways as targets for the treatment of inflammatory bowel diseases. Gastroenterology. 2019;157:1032–1043.e1.
Article
CAS
PubMed
Google Scholar
Olsen T, Goll R, Cui G, et al. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine. 2009;46:222–7.
Article
CAS
PubMed
Google Scholar
Rismo R, Olsen T, Cui G, et al. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease. Scand J Gastroenterol. 2013;48:311–9.
Article
CAS
PubMed
Google Scholar
Johnsen KM, Goll R, Hansen V, et al. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm. Eur J Gastroenterol Hepatol. 2017;29:98–104.
Article
CAS
PubMed
Google Scholar
Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol. 2018;11:1756283x17745029.
Article
PubMed
PubMed Central
Google Scholar
Siegel CA, Refocusing IBD. Patient management: personalized, proactive, and patient-centered care. Am J Gastroenterol. 2018;113:1440–3.
Article
PubMed
Google Scholar
Weimers P, Munkholm P. The natural history of IBD: lessons learned. Curr Treat Options Gastroenterol. 2018;16:101–11.
Article
PubMed
Google Scholar
de Souza HSP. Etiopathogenesis of inflammatory bowel disease: today and tomorrow. Curr Opin Gastroenterol. 2017;33:222–9.
Article
PubMed
Google Scholar
Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw. 2017;17:25–40.
Article
PubMed
PubMed Central
Google Scholar
Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut. 2017;66:50–8.
Article
PubMed
Google Scholar
Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991–1030.
Article
PubMed
Google Scholar
Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med. 2005;352:2499–507.
Article
CAS
PubMed
Google Scholar
Olsen T, Goll R, Cui G, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007;42:1312–20.
Article
CAS
PubMed
Google Scholar
Cui G, Olsen T, Christiansen I, et al. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand J Clin Lab Invest. 2006;66:249–59.
Article
CAS
PubMed
Google Scholar
Olsen T, Rismo R, Gundersen MD, et al. Normalization of mucosal tumor necrosis factor-alpha: a new criterion for discontinuing infliximab therapy in ulcerative colitis. Cytokine. 2016;79:90–5.
Article
CAS
PubMed
Google Scholar
Diab J, Al-Mahdi R, Gouveia-Figueira S, et al. A quantitative analysis of colonic mucosal Oxylipins and Endocannabinoids in treatment-naive and deep remission ulcerative colitis patients and the potential link with cytokine gene expression. Inflamm Bowel Dis. 2019;25:490–7.
Article
PubMed
Google Scholar
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5.
Article
CAS
PubMed
Google Scholar
Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.
Article
PubMed
Google Scholar
D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660–7.
Article
CAS
PubMed
Google Scholar
Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.
Article
CAS
PubMed
Google Scholar
Burisch J, Kiudelis G, Kupcinskas L; Epi-IBD group, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019;68:423–33.
Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:531–8.
Article
PubMed
Google Scholar
Schniers A, Anderssen E, Fenton CG, et al. The proteome of ulcerative colitis in colon biopsies from adults - optimized sample preparation and comparison with healthy controls. Proteomics Clin Appl. 2017;11. https://doi.org/10.1002/prca.201700053. https://onlinelibrary.wiley.com/action/showCitFormats?doi=10.1002%2Fprca.201700053.
Taman H, Fenton CG, Hensel IV, et al. Genome-wide DNA methylation in treatment-naive ulcerative colitis. J Crohns Colitis. 2018;12:1338–47.
Article
PubMed
PubMed Central
Google Scholar
Taman H, Fenton CG, Hensel IV, et al. Transcriptomic landscape of treatment-naive ulcerative colitis. J Crohns Colitis. 2018;12:327–36.
Article
PubMed
Google Scholar
Schniers A, Goll R, Pasing Y, et al. Ulcerative colitis: functional analysis of the in-depth proteome. Clin Proteomics. 2019;16:4.
Article
PubMed
PubMed Central
Google Scholar
Diab J, Hansen T, Goll R, et al. Lipidomics in ulcerative colitis reveal alteration in mucosal lipid composition associated with the disease state. Inflamm Bowel Dis. 2019;25:1780–7.
Article
PubMed
Google Scholar